Philadelphia, PAData from the National Lung Cancer Screening Trial (NLST)conducted by the American College of Radiology Imaging Network and National Cancer Institute Lung Screening Studyprovided researchers the opportunity to investigate the probability that a cancer detected with screening low-dose computed tomography (LDCT) would not have progressed to become life threatening. The results of this investigation published online today in JAMA Internal Medicine suggest that up to 18 percent of the cancers detected by LDCT may not have progressed enough to affect patient health if left undetected.
"This is another piece of important information that helps us to better understand the benefits and risks of lung cancer screening," says the study's lead author, Edward F. Patz, Jr., M.D., a professor of radiology, and pharmacology and cancer biology at Duke University School of Medicine.
"The NLST provided encouraging data demonstrating that lung cancer screening with CT reduces death from the disease. However, there are inherent risks with any mass screening program, and this paper investigates the probability of overdiagnosismeaning, if some patients never would have been screened for lung cancer, they would never have known they had the disease because it would never have caused symptom."
The specific negative consequences of overdiagnosis described by the authors include unnecessary invasive diagnostic procedures, treatment, morbidity (and mortality in rare cases), follow-up, cost, patient anxiety, and labeling of patients with a disease that otherwise would never have been detected.
Using NLST data, the authors determined an "upper bound to true overdiagnosis rate" because the post-screening follow-up period in NLST may not have been long enough to totally differentiate overdiagnosis from the effects of lead timethe length of time a diagnosis was moved up due to early detection by screening. The probability that any l
|Contact: Shawn Farley|
American College of Radiology